Working… Menu
Trial record 1 of 1 for:    NCT01303146
Previous Study | Return to List | Next Study

Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation (Azylis)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01303146
Recruitment Status : Completed
First Posted : February 24, 2011
Last Update Posted : February 24, 2011
European Leukodystrophy Association
Zymenex A/S
Information provided by:
Assistance Publique - Hôpitaux de Paris

Brief Summary:
There is currently no effective treatment for late infantile MLD once clinical symptoms are evident. METAZYM is a recombinant human arylsulfatase A developed for an intravenous ERT for the treatment of late infantile MLD. The overall objective of this study is to evaluate the efficacy and safety of intravenous rhASA treatment in a patient with late infantile MLD who had previously received hematopoietic stem cell transplantation (HCT).

Condition or disease Intervention/treatment Phase
Metachromatic Leukodystrophy Drug: rhARSA Phase 2

Detailed Description:
Metachromatic Leukodystrophy (MLD) is a rare autosomal recessive disorder caused by the deficiency of the Arylsulfatase A enzyme (ARSA), resulting in accumulation of galactosyl sulfatide (cerebroside sulfate), a major constituent of the myelin sheath. Accumulation of galactosyl sulfatides leads to a progressive degeneration of the white matter in the central and peripheral nervous system (CNS, PNS) and neuronal degeneration. The late infantile form of MLD, which usually is diagnosed in the second year of life, is the most frequent and severe form of the disease. The prognosis is severe, leading to vegetative stage or death within few years after the diagnosis. There is no treatment for patients affected with this early onset form of the disease. In patients with late-onset MLD (juvenile and adult forms), allogeneic hematopoietic stem cell transplantation can stabilize the cerebral demyelination. This treatment is however inefficient in patients with late infantile MLD at a symptomatic stage. The overall objective is to evaluate the efficacy and safety of rhASA treatment in a patient with late infantile MLD who had received HCT at a presymptomatic stage of the disease. Patient will receive rhARSA (100 U/kg) intravenously every other week for a period of 18 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: and Safety of METAZYM (Recombinant Human Arylsulfatase A or rhASA) for the Treatment of Patients With Late Infantile MLD Who Had Previously Hematopoietic Stem Cell Transplantation
Study Start Date : October 2008
Actual Primary Completion Date : March 2010
Actual Study Completion Date : April 2010

Arm Intervention/treatment
Experimental: Enzyme replacement therapy
intravenous infusion 100U/kg every other week for 18 months
Drug: rhARSA
intravenous infusion 100U/kg every other week for 18 months
Other Names:
  • HGT-1111
  • Metazym

Primary Outcome Measures :
  1. Efficacy of METAZYM on peripheral nerve function by electrophysiological studies (motor and sensory nerves conduction velocities) every 6 months; [ Time Frame: every 6 months ]
  2. Efficacy of METAZYM on peripheral nerve sulfatide storage and demyelination by nerve biopsy at baseline and week 26; [ Time Frame: week 26 ]
  3. Efficacy of METAZYM on functional capacity by assessing motor function (GMFM) every 6 months [ Time Frame: every 6 months ]

Secondary Outcome Measures :
  1. Efficacy of METAZYM on central nervous system involvement by evaluation of cognitive and neurological function, somatosensory and auditory evoked potentials, and brain MRI every 6 months; [ Time Frame: every 6 months ]
  2. Safety profile of METAZYM by monitoring AE's, vital sign parameters and physical examination findings before each injection, as well as ECGs and routine clinical laboratory tests every 3 months. [ Time Frame: every 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities.
  • The patient must have a confirmed diagnosis of MLD as defined by:ARSA activity < 10 nmol/h/mg in leukocytes prior to HCT; Presence of elevated sulfatide in urine prior to HCT
  • The patient must have a residual level of voluntary function (as judged by the investigator), including presence of residual cognitive function (attention, executive and visual functions) as well as the presence of residual voluntary motor function in one upper or lower limb as a minimum.
  • The patient must have an age at the time of screening ≥ 6 months
  • The patient must have had onset of symptoms before the age of 4 years
  • The subject and his/her guardian(s) must have the ability to comply with the clinical protocol
  • The patients' medical record must document that the legal guardian(s) has had independent counselling or a consultation regarding stem cell transplantation in order to assure that the guardian(s) is fully informed regarding the risks and benefits of this alternative

Exclusion Criteria:

Patient will be excluded from this study if they do not meet the specific inclusion criteria, or if any of the following criteria apply:

  • Presence of a gross motor function measure (GMFM < 25)
  • Presence of severe pseudo-bulbar signs (weakness and disco-ordination of tongue and swallowing muscles leading to severe difficulty with swallowing)
  • Spasticity so severe to inhibit transportation
  • Known multiple sulfatase deficiency
  • Presence of major congenital abnormality
  • Presence of known chromosomal abnormality and syndromes affecting psychomotor development
  • Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical condition
  • Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial
  • Use of any investigational product within 30 days prior to study enrolment or currently enrolled in another study which involves clinical investigations
  • Received ERT with rhASA from any source

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01303146

Layout table for location information
Department of Pediatric Endocrinology and Neurology, Saint Vincent de Paul Hospital
Paris, France, 75014
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
European Leukodystrophy Association
Zymenex A/S
Layout table for investigator information
Study Chair: Patrick Aubourg, MD, PhD Department of Pediatric Endocrinology and Neurology, Saint Vincent de Paul Hospital, Paris
Layout table for additonal information
Responsible Party: VACHER Yannick, Department of Clinical Research of developpement Identifier: NCT01303146    
Other Study ID Numbers: P070805
First Posted: February 24, 2011    Key Record Dates
Last Update Posted: February 24, 2011
Last Verified: February 2011
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Metachromatic Leukodystrophy
Enzyme replacement therapy
Allogeneic hematopoietic stem cell transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukodystrophy, Metachromatic
Hereditary Central Nervous System Demyelinating Diseases
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Lysosomal Storage Diseases, Nervous System
Demyelinating Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders